<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999930</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2019-462</org_study_id>
    <nct_id>NCT04999930</nct_id>
  </id_info>
  <brief_title>Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)</brief_title>
  <official_title>Comparison of Clinical Efficacy and Patient's Satisfaction of Tiotropium Respimat Administration With and Without Aerochamber in Patient With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD patient on Tiotropium Respimart divided into two group, Group A given aerochamber and&#xD;
      Group B without aerochamber enroll in the study for total 18 week .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. COPD patient who is on Tiotropium Respimart and other inhalers continued.&#xD;
&#xD;
        2. Those fullfill inclusion criteria will be randomized into two group.&#xD;
&#xD;
        3. To do Baseline CAT score and SGRQ questionnaires with Lung function test.&#xD;
&#xD;
        4. Assess inhaler technique with and without aerochamber.&#xD;
&#xD;
        5. Teach proper inhaler technique by templates and demonstrate to patients.&#xD;
&#xD;
        6. Group A given aerochamber and Group B without aerochamber enroll in the study for total&#xD;
           18 week .&#xD;
&#xD;
        7. First phase for 8 week after that 2 week of washout periode (without aerochamber both&#xD;
           arm).&#xD;
&#xD;
        8. Then Group A without aerochamber and Group B with aerochamber continue with all inhalers&#xD;
           for 8 week.&#xD;
&#xD;
        9. Followed up at 8th , 11th and 18th week to assess inhaler techniques ,Lung function test&#xD;
           and do CAT score, and SGRQ questionnaire.&#xD;
&#xD;
       10. Analysis data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the frequency of exacerbation (number of events ) and hospital admission (number of admissions) using tiotropium with and without aerochamber</measure>
    <time_frame>18 weeks</time_frame>
    <description>Comparing frequency of exacerbation (number of events ) and hospital admission (number of admissions) in both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of FEV1 (%) between the treatment group</measure>
    <time_frame>18 weeks</time_frame>
    <description>Comparing differences of lung function (FEV1 %) in both groups after cross-over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of inhaler technique error between the group</measure>
    <time_frame>18 weeks</time_frame>
    <description>Comparing inhaler errors in both groups based on the checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life (SGRQ questionaire)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess patients satisfaction and preference, attitudes, and perceptions about their inhalers using questionnaire</measure>
    <time_frame>18 weeks</time_frame>
    <description>Scale of 0-5, (0-very easy, 5-hard)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with aerochamber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>without aerochamber</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aerochamber</intervention_name>
    <description>efficacy and patients satisfaction</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Tiotropium respimart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. COPD patients under Respiratory clinic UKM follow up&#xD;
&#xD;
               -  Patients who are with stable COPD (no exacerbation past 2 months)&#xD;
&#xD;
               -  Age same and more than 40-year-old&#xD;
&#xD;
          2. Patient able to perform inhaler medication&#xD;
&#xD;
          3. Patient able to perform technically acceptable pulmonary function test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Drug hypersensitivity&#xD;
&#xD;
          2. Bronchial Asthma&#xD;
&#xD;
          3. Significant disease that may influence patient's ability to participate in the study.&#xD;
&#xD;
          4. Unable to provide signed informed consent&#xD;
&#xD;
          5. Mental condition rendering the subject unable to understand the nature, scope and the&#xD;
             possible consequences of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National University of Malaysia</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>50600</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Mohamed Faisal Abdul Hamid</investigator_full_name>
    <investigator_title>Associate Professor Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

